<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03718273</url>
  </required_header>
  <id_info>
    <org_study_id>BRAKE-AF</org_study_id>
    <secondary_id>2018-001936-23</secondary_id>
    <nct_id>NCT03718273</nct_id>
  </id_info>
  <brief_title>IvaBRAdine blocK of Funny Current for Heart Rate Control in permanEnt Atrial Fibrillation. (BRAKE-AF Study).</brief_title>
  <acronym>BRAKE-AF</acronym>
  <official_title>A Phase III Clinical Trial to Compare Ivabradine Versus Digoxin in the Heart Rate Control in Patients With Permanent Atrial Fibrillation Under Treatment With Beta-blockers or Calcium Antagonists.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adolfo Fontenla</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Spanish Clinical Research Networt (SCReN)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Carlos III Health Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Universitario 12 de Octubre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The BRAKE-AF Study is a phase III, randomised, controlled, multicentric, open-label clinical
      trial to prove the noninferiority of ivabradine versus digoxin in the treatment of permanent
      atrial fibrillation. The total duration of the study is 3 years, with 24 months of enrolment,
      treatment and follow-up.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a non-commercial, investigator-driven clinical study funded through a public
      competitive call by Instituto de Salud Carlos III, Spanish Ministry of Economy (PI17/01272).

      The study is coordinated by the main investigator from Hospital Universitario 12 de Octubre
      in Madrid; the sponsorship is performed by Dr. Adolfo Fontenla (Hospital Universitario 12 de
      Octubre). Several responsibilities are delegated to the Clinical Research Unit (Hospital 12
      de Octubre, Madrid, Spain).

      The study was planned according to the Good Clinical Practices. BRAKE-AF Study has been
      approved by the Ethics Committee and Spanish Health Authorities. All participating patients
      must give written informed consent before any study procedure occur.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 19, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Heart rate reduction.</measure>
    <time_frame>3 months</time_frame>
    <description>Reduction of the mean daytime heart rate registered in Holter- electrocardiogram (ECG) after treatment with Ivabradine or Digoxin.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serious adverse events</measure>
    <time_frame>3 months</time_frame>
    <description>Proportion of patients experiencing syncope, severe bradycardia or any serious adverse reaction requiring hospitalization, emergency visit or death of the patient during treatment with Ivabradine or Digoxin.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction in the scale of atrial fibrillation (AF) symptoms according to the European Hearth Rhythm Association (EHRA) Score modified.</measure>
    <time_frame>Months 1 and 3.</time_frame>
    <description>Percentage of patients who experience a reduction in the scale of atrial fibrillation. symptoms according to the EHRA Score modified.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 minute walk test (6MWT).</measure>
    <time_frame>Baseline and after 3 months.</time_frame>
    <description>Increase in meters in the 6MWT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality-of-Life Short Form 36 (SF-36) Health Survey (QoL SF-36) Score.</measure>
    <time_frame>At baseline and 3 months.</time_frame>
    <description>Increase in the score obtained in global quality of life parameters analyzed by the SF-36 questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Atrial Fibrillation Effect on Quality-of-Life (QoL AFEQT) score.</measure>
    <time_frame>At baseline and 3 months</time_frame>
    <description>Increase in the score obtained in parameters of quality of life quality of life associated with AF analyzed by the AFEQT questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of the daytime Health rate.</measure>
    <time_frame>1 month</time_frame>
    <description>Reduction of the average daytime Heart Rate (HR) recorded in Holter-ECG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of resting Health Rate.</measure>
    <time_frame>1 and 3 months</time_frame>
    <description>Reduction of resting heart rate (HR) recorded on one electrocardiogram (ECG).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of the maximum heart rate (HR) recorded.</measure>
    <time_frame>1 and 3 months</time_frame>
    <description>Reduction of the maximum HR recorded in Holter-ECG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of the mean HR recorded.</measure>
    <time_frame>1 and 3 months</time_frame>
    <description>Reduction of the mean HR in 24 hours recorded in Holter-ECG .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of the HR delta.</measure>
    <time_frame>1 and 3 months</time_frame>
    <description>Reduction of the HR delta (difference between maximum HR and mean HR in 24 hours) recorded in Holter-ECG.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of HR in moderate exercise.</measure>
    <time_frame>3 months</time_frame>
    <description>Reduction of HR in moderate exercise (maximum HR measured by Holter-ECG during the 6-minute walk test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with non-severe bradycardia.</measure>
    <time_frame>1 and 3 months</time_frame>
    <description>Percentage of patients who experience non-severe bradycardia during the study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients who experience any adverse reaction.</measure>
    <time_frame>1 and 3 months</time_frame>
    <description>Percentage of patients who experience any adverse reaction to the study drugs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients who voluntarily abandon the study drugs.</measure>
    <time_frame>3 months</time_frame>
    <description>Percentage of patients who voluntarily abandon the study drugs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of hospitalizations, emergency visits and mortality due to a major cardiovascular event.</measure>
    <time_frame>3 months</time_frame>
    <description>Proportion of patients experiencing hospitalizations, emergency visits and mortality due to a major cardiovascular event during treatment with the study drug.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">232</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Heart Diseases</condition>
  <arm_group>
    <arm_group_label>Digoxin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Digoxin 0,25 mg. The initial dose will be based on whether there are factors such as age over 80 years, weight under 60 kg and creatinine clearance &lt;60ml / min,</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ivabradine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ivabradine 5 mg, twice a day the first month administered by mouth. If the tolerance is good, the dose will be increased to 7.5 mg on month 2 and will continue until the third month.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivabradine</intervention_name>
    <description>Ivabradine 5 mg, twice a day the first month administered by mouth. If the tolerance is good, the dose will be increased to 7.5 mg on month 2 and will continue until the third month.
Patients with 75 or more years of age will receive an initial dose of 2.5 mg / twice a day, which can be increased to 5 mg / twice a day in week 7 and to 7.5 mg in month 1 if the tolerance has been good</description>
    <arm_group_label>Ivabradine</arm_group_label>
    <other_name>Ivabradine 5 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Digoxin</intervention_name>
    <description>The initial dose will be based on whether there are factors such as age over 80 years, weight less than 60 kg and creatinine clearance &lt;60ml / min, if there is no factor, the oral dose will be 0.25mg / 24h. If there are 2 factors, the dose will be 0.15 mg / 24 h. and if there are 2 or 3 factors, the dose will be 0.10 mg / 24 h.</description>
    <arm_group_label>Digoxin</arm_group_label>
    <other_name>Digoxin 0,25 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 18 years.

          2. Permanent Atrial Fibrillation (AF) at the time of randomization, with no prospect of
             cardioversion, antiarrhythmic treatment with group I or III drugs, or pulmonary vein
             ablation.

          3. Symptoms attributable to AF associated with the presence of at least one of the
             following inadequate Heart rate (HR) control criteria:

               1. HR at rest &gt; 110 bpm (on ECG -electrocardiogram- performed in the 14 days prior
                  to inclusion).

               2. HR at rest between 80 and 110 bpm (on ECG performed in the 14 days prior to
                  inclusion) and at least one of the following criteria:

             i. HR in exercise of moderate intensity &gt; 130 bpm (measured in an ergometry or in a
             Holter-ECG performed in the 60 days prior to inclusion).

             ii. Average daytime HR &gt; 80 bpm (measured on a Holter-ECG performed in the 60 days
             prior to inclusion).

          4. Be receiving treatment with beta-blockers or non-dihydropyridine calcium channel
             blockers (verapamil or diltiazem) at the maximum dose recommended or tolerated by the
             patient.

          5. Be able to voluntarily give their informed consent.

          6. B|ood test carried out in the 6 months prior to inclusion' including: blood count,
             thyroid hormones and creatinine, in order to rule out secondary causes of poor HR
             control. The creatinine figure will be used to calculate the creatinine clearance in
             order to adjust the dose of patients who are randomized to the Digoxin group.

          7. Transthoracic echocardiogram to rule out, eg, severe valvular heart disease,
             hypertrophic cardiomyopathy. The one performed in the year prior to inclusion in the
             study will be considered acceptable provided that the patient's clinical situation has
             been stable in that period of time.

        Exclusion Criteria:

          1. Previous treatment or patients with a known contraindication to Ivabradine or Digoxin
             or to any excipient of both drugs.

          2. Paroxysmal or intermittent complete atrioventricular (AV) block in patients not
             carrying a pacemaker.

          3. Decompensated heart failure requiring inotropic and I or intravenous diuretics in the
             week prior to randomization or in New York Heart Association (NYHA) functional class
             IV or on the cardiac transplant waiting list,

          4. Acute pericarditis, acute myocarditis or constrictive pericarditis.

          5. Obstructive hypertrophic cardiomyopathy.

          6. Valvular disease requiring surgical or percutaneous correction.

          7. Medical causes that justify poor control of heart rate: fever' anemia,
             hyperthyroidism, pheochromocytoma' etc.

          8. Severe hypotension (blood pressure &lt;90/50 mmHg).

          9. Concomitant treatment with potent cytochrome P450 3A4 inhibitors such as azole
             antifungals (ketoconazole, itraconazole), macrolide antibiotics (clarithromycin, oral
             erythromycin, josamycin, telithromycin) HIV protease inhibitors (nelfinavir,
             ritonavir) and nefazodone.

         10. Severe renal insufficiency (CrCl &lt;30 ml/Kg/min) or in a hemodialysis program.

         11. Severe hepatic insufficiency.

         12. Major surgery (including cardiac surgery) in the month prior to randomization.

         13. Severe concomitant illness that supposes a llfe expectancy of less than one year.

         14. Impossibility of carrying out scheduled visits to the protocol.

         15. Woman of childbearing age (under 50 years of age, except for those who present a
             gynecological report that proves the presence of menopause) and women who are
             breastfeeding.

         16. Participation in a clinical trial in the previous 6 months.

         17. Patients with acute myocardial infarction or unstable angina.

         18. Patient with a recent stroke.

         19. Patients with congenital long QT syndrome or treated with drugs that prolong this
             interval.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adolfo Fontenla, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Universitario 12 de Octubre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Adolfo Fontenla, MD, PhD</last_name>
    <phone>+34 91 390 80 70</phone>
    <email>adolforamon.fontela@salud.madrid.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>María López Gil, MD, PhD</last_name>
    <phone>+34 91 390 80 70</phone>
    <email>mlopezgil@secardiologia.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitario de Burgos</name>
      <address>
        <city>Burgos</city>
        <zip>09006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ricardo Salgado Aranda, MD, PhD</last_name>
      <phone>+34 94 721 33 40</phone>
      <email>rsala@saludcastillayleon.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro</name>
      <address>
        <city>Madrid</city>
        <zip>28022</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jorge Toquero Ramos, MD, PhD</last_name>
      <phone>+34 91 191 74 08</phone>
      <email>jorgetoquero@secardiologia.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberto Matía Francés, MD, PhD</last_name>
      <phone>+34 91 336 80 00</phone>
      <email>roberto.matia@salud.madrid.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundación Jiménez Díaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ángel L. Miracle Blanco, MD, PhD.</last_name>
      <phone>+34 91 550 48 00</phone>
      <email>angel.miracle@quironsalud.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adolfo Fontenla Cerezuela, MD, PhD</last_name>
      <phone>+34 91 390 80 70</phone>
      <email>adolforamon.fontela@salud.madrid.org</email>
    </contact>
    <contact_backup>
      <last_name>María López Gil, MD, PhD</last_name>
      <phone>+34 91 390 80 70</phone>
      <email>mlopezgil@secardiología.es</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan R. Rey Blas, MD, PhD</last_name>
      <phone>+34 91 7277000</phone>
      <email>juanr.rey@salud.madrid.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Getafe</name>
      <address>
        <city>Madrid</city>
        <zip>28905</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agustín Pastor, MD, PhD</last_name>
      <phone>+34 91 683 93 60</phone>
      <email>agustin.pastor@salud.madrid.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Rey Juan Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28933</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Mejía Martínez, MD, PhD</last_name>
      <phone>+34 91 481 62 25</phone>
      <email>elena.mejia@hospitalreyjuancarlos.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Salud</name>
      <address>
        <city>Toledo</city>
        <zip>45004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miguel A. Arias Palomares, MD, PhD</last_name>
      <phone>+34 92 526 92 00</phone>
      <email>maapalomares@secardiologia.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>October 18, 2018</study_first_submitted>
  <study_first_submitted_qc>October 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 24, 2018</study_first_posted>
  <last_update_submitted>January 12, 2020</last_update_submitted>
  <last_update_submitted_qc>January 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitario 12 de Octubre</investigator_affiliation>
    <investigator_full_name>Adolfo Fontenla</investigator_full_name>
    <investigator_title>Adolfo Fontenla, MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Ivabradine</keyword>
  <keyword>Digoxin</keyword>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>Heart rate control</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Digoxin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

